STOCK TITAN

Hemogenyx Pharmaceuticals Plc - HOPHF STOCK NEWS

Welcome to our dedicated news page for Hemogenyx Pharmaceuticals Plc (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharmaceuticals Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hemogenyx Pharmaceuticals Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hemogenyx Pharmaceuticals Plc's position in the market.

Rhea-AI Summary
Hemogenyx Pharmaceuticals plc announces a breakthrough in delivering Chimeric Bait Receptors (CBR) into the brain via programmed microglial cells for treating brain cancers and neurodegenerative diseases. The method involves genetically modified autologous hematopoietic stem cells. This innovation could potentially offer long-term protection and a renewable source of treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc announces successful in vivo demonstration of intranasal delivery of Chimeric Bait Receptor for combating airborne viral infections. The proprietary technology aims to program immune cells to eliminate viruses, with efficient delivery and potential cost-effectiveness. AI tools and in-house mRNA synthesis accelerate research efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has received approval from the U.S. FDA to proceed with Phase I clinical trials for HEMO-CAR-T, a potential treatment for acute myeloid leukemia (AML). The FDA lifted the clinical hold on the Investigational New Drug (IND) application after the Company addressed all issues satisfactorily. CEO Dr. Vladislav Sandler expressed excitement for the opportunity to accelerate clinical development and provide a potentially life-saving treatment for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced the approval and issuance of a U.S. Conditioning Patent for a method of eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) in a patient using Bi-Specific Antibodies. The CEO, Dr. Vladislav Sandler, expressed excitement about the decision, emphasizing the significance of this patent protection for CDX, one of the company's key product candidates for the future. This development reinforces the company's position as a leader in the area of conditioning bone marrow transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has submitted a complete response to the previously announced Clinical Hold of the Investigational New Drug application to the US Food and Drug Administration for HEMO-CAR-T. The submission is necessary to apply for the lifting of the Clinical Hold, which is needed to obtain consent from the FDA to commence Phase I clinical trials of HEMO-CAR-T. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, expressed optimism about the filing, stating that they are pleased to have addressed the FDA's concerns and look forward to becoming a clinical stage biopharmaceutical company once consent is received from the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (HEMO) announces successful completion of Process Qualification run for HEMO-CAR-T cells, addressing FDA concerns and moving forward with clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Hemogenyx Pharmaceuticals (HEMO) successfully raised £534,375 through the allotment and issue of 22,500,000 new ordinary shares at 2.375 pence per share. The Placing will be used to advance the Company's CAR-T cells for AML treatment and provide additional resources to the CBR platform. The Placing Shares will be admitted to trading on the London Stock Exchange Main Market on December 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals (HEMO) announces promising results for the potential use of its Chimeric Bait Receptor platform in the treatment of Non-Hodgkin Lymphoma (NHL) and solid tumors. The company's AI-based protein structure simulations and in-house mRNA synthesis have accelerated R&D efforts, showing potential for treating relapsed and/or refractory stage III/IV metastasized NHL and solid tumors like epithelial ovarian cancer and certain carcinomas. Preliminary tests against live infectious SARS-CoV-2 also show promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has successfully completed the re-manufacturing of an improved lentivirus devoid of splice variants, essential for the development of their HEMO-CAR-T cells to treat acute myeloid leukaemia. The re-manufacturing resolves the clinical hold imposed by the FDA, allowing the company to move forward with the IND application and subsequent clinical trials. CEO Dr Vladislav Sandler expressed optimism about the clear path to lifting the clinical hold and the company's commitment to expeditiously resubmit the IND.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc announces that the total issued share capital of the Company consists of 1,153,065,988 ordinary shares. None of the shares are held in treasury. The total number of voting rights in the Company is 1,153,065,988.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Hemogenyx Pharmaceuticals Plc

OTC:HOPHF

HOPHF Rankings

HOPHF Stock Data

47.69M
1.01B
12.58%
0.94%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
50 Jermyn Street